Citadel Advisors’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.56M | Buy |
12,000
+3,000
| +33% | +$971K | ﹤0.01% | 4931 |
|
|
2025
Q4 | $2.73M | Buy |
9,000
+2,300
| +34% | +$753K | ﹤0.01% | 5341 |
|
|
2025
Q3 | $2.28M | Buy |
6,700
+1,600
| +31% | +$486K | ﹤0.01% | 5810 |
|
|
2025
Q2 | $1.23M | Sell |
5,100
-7,000
| -58% | -$1.72M | ﹤0.01% | 6633 |
|
|
2025
Q1 | $3.29M | Buy |
12,100
+4,400
| +57% | +$1.03M | ﹤0.01% | 4597 |
|
|
2024
Q4 | $1.42M | Buy |
7,700
+1,700
| +28% | +$347K | ﹤0.01% | 6340 |
|
|
2024
Q3 | $1.35M | Buy |
6,000
+4,300
| +253% | +$774K | ﹤0.01% | 6262 |
|
|
2024
Q2 | $243K | Sell |
1,700
-3,200
| -65% | -$493K | ﹤0.01% | 9551 |
|
|
2024
Q1 | $766K | Sell |
4,900
-1,600
| -25% | -$258K | ﹤0.01% | 7484 |
|
|
2023
Q4 | $1.17M | Sell |
6,500
-3,900
| -38% | -$706K | ﹤0.01% | 6369 |
|
|
2023
Q3 | $1.87M | Buy |
10,400
+4,300
| +70% | +$851K | ﹤0.01% | 5336 |
|
|
2023
Q2 | $1.09M | Sell |
6,100
-75,200
| -92% | -$17.3M | ﹤0.01% | 6290 |
|
|
2023
Q1 | $17.5M | Buy |
81,300
+63,600
| +359% | +$15.3M | ﹤0.01% | 2068 |
|
|
2022
Q4 | $3.89M | Buy |
17,700
+6,200
| +54% | +$1.14M | ﹤0.01% | 4285 |
|
|
2022
Q3 | $1.55M | Sell |
11,500
-10,200
| -47% | -$1.75M | ﹤0.01% | 6091 |
|
|
2022
Q2 | $3.51M | Buy |
21,700
+2,100
| +11% | +$328K | ﹤0.01% | 4467 |
|
|
2022
Q1 | $3.7M | Buy |
19,600
+3,800
| +24% | +$808K | ﹤0.01% | 4763 |
|
|
2021
Q4 | $4.28M | Sell |
15,800
-3,600
| -19% | -$1.22M | ﹤0.01% | 4612 |
|
|
2021
Q3 | $7.04M | Buy |
19,400
+13,000
| +203% | +$4.25M | ﹤0.01% | 3668 |
|
|
2021
Q2 | $2.2M | Sell |
6,400
-11,600
| -64% | -$3.84M | ﹤0.01% | 6361 |
|
|
2021
Q1 | $6.26M | Buy |
18,000
+5,800
| +48% | +$1.92M | ﹤0.01% | 3795 |
|
|
2020
Q4 | $3.15M | Sell |
12,200
-4,100
| -25% | -$1.13M | ﹤0.01% | 4515 |
|
|
2020
Q3 | $4.67M | Buy |
16,300
+5,800
| +55% | +$1.36M | ﹤0.01% | 3269 |
|
|
2020
Q2 | $1.98M | Sell |
10,500
-15,800
| -60% | -$2.57M | ﹤0.01% | 4602 |
|
|
2020
Q1 | $3.24M | Buy |
26,300
+13,400
| +104% | +$2.1M | ﹤0.01% | 3333 |
|
|
2019
Q4 | $2.14M | Sell |
12,900
-32,100
| -71% | -$5.33M | ﹤0.01% | 4311 |
|
|
2019
Q3 | $5.51M | Sell |
45,000
-6,300
| -12% | -$837K | ﹤0.01% | 2978 |
|
|
2019
Q2 | $6.36M | Buy |
51,300
+44,400
| +643% | +$5.64M | ﹤0.01% | 2755 |
|
|
2019
Q1 | $911K | Sell |
6,900
-15,900
| -70% | -$2.15M | ﹤0.01% | 5750 |
|
|
2018
Q4 | $3.2M | Buy |
22,800
+12,700
| +126% | +$1.68M | ﹤0.01% | 3424 |
|
|
2018
Q3 | $1.74M | Sell |
10,100
-6,000
| -37% | -$1.01M | ﹤0.01% | 4638 |
|
|
2018
Q2 | $2.48M | Buy |
+16,100
| New | +$2.87M | ﹤0.01% | 3768 |
|
Other funds holding ONC
BBA
HA
SL
Citadel Advisors's ONC Position: Q1 2026 in Review
Citadel Advisors increased its BeOne Medicines Ltd (ONC) stake by 93% in Q1 2026, buying an estimated $161M and bringing the position to 1,032,298 shares worth $307M. The position accounts for 0.05% of the portfolio, ranked #305.
Citadel Advisors first reported a position in ONC in Q2 2018 and has held it in 31 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.
- Citadel Advisors held 1,032,298 shares of BeOne Medicines Ltd worth $307M as of Q1 2026.
- Citadel Advisors bought 498,781 BeOne Medicines Ltd shares in Q1 2026, an estimated $161M.
- BeOne Medicines Ltd made up 0.05% of Citadel Advisors's portfolio in Q1 2026, its #305 holding.
- Citadel Advisors first reported a position in BeOne Medicines Ltd in Q2 2018 and has held it in 31 quarters since.
- 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.